Breast. 2017 Sep 13;36:25-30. [Epub ahead of print]
Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review.
Mengchuan Wang, Jian Zhang, Shufeng Ji, Guoli Shao, Kankan Zhao, Zixiang Wang, Aiguo Wu.
Zhujiang Hospital, The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
A systematic review was conducted to evaluate the safety and efficacy of TACE on patients of BCLM.
TACE is appropriate for patients who are not suitable to surgery or systematic chemotherapy.
Toxic side effects should be monitored after TACE is performed.
BACKGROUND: There is limited data on the impact of transarterial chemoembolisation (TACE) on survival in patients of breast cancer with liver metastasis (BCLM).
METHODS: A systematic review was conducted to assess TACE effect on BCLM patients. A search for clinical studies published since 1/1/2000 to 1/1/2017 was performed. Survival data from all studies were extracted to evaluate the efficacy of TACE, including overall survival, disease free survival and response rate. Toxic side effects data were also extracted to assess the safety of TACE.
RESULTS: A total of 10 studies with 519 BCLM patients were identified. 78.0% patients were treated with TACE, 9.9% were treated with TACE plus systematic chemotherapy and 12.1% were treated with systematic chemotherapy alone. Pooled median overall survival of patients who received TACE ranged from 7.3 to 47.0 months, median disease free survival ranged from 2.9 to 17.0 months and response rates ranged from 7.0 to 73.5%. Pooled Grade 3 and 4 side effects (blood toxicities, liver toxicity and post-embolization syndrome) ranged from 0.0 to 17.4%.
CONCLUSIONS: TACE is one of an effective treatment for BCLM and whether a specific patient is appropriate to receive TACE depends on a multiple disciplinary team discussion.
KEYWORDS: Breast cancer with liver metastasis, Transarterial chemoembolisation